share_log

Piper Sandler Maintains Overweight on Akoya Biosciences, Lowers Price Target to $8

Piper Sandler Maintains Overweight on Akoya Biosciences, Lowers Price Target to $8

派珀·桑德勒维持对Akoya Biosciences的增持,将目标股价下调至8美元
Benzinga ·  2023/11/13 16:09

Piper Sandler analyst David Westenberg maintains Akoya Biosciences (NASDAQ:AKYA) with a Overweight and lowers the price target from $11 to $8.

派珀·桑德勒分析师戴维·韦斯滕伯格维持Akoya Biosciences(纳斯达克股票代码:AKYA)增持 “增持”,并将目标股价从11美元下调至8美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发